遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途

Title:

遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途

Document Type and Number:

Japanese Patent JP7003354

Kind Code:

B2

Abstract:

Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose.

More Like This:

WO/2005/092376	CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF MCSP
WO/2020/241660	PREVENTIVE OR THERAPEUTIC AGENT FOR DIABETIC RETINOPATHY
JP2022537887	Trispecific binding molecules for BCMA and uses thereof

Inventors:

Schlanz, jennifer
Edelman, Burt
Chang, Yang

Application Number:

JP2018528702A

Publication Date:

March 04, 2022

Filing Date:

December 09, 2016

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Takeda GmbH

International Classes:

A61K39/395; A61K31/195; A61K31/58; A61K38/08; A61K38/12; A61K45/00; A61K47/02; A61K47/12; A61K47/22; A61K47/26; A61P7/10; A61P9/00; A61P43/00

Foreign References:

WO2015112578A1
WO2014152232A1
WO2016160926A1

Other References:

Study NCT02586805 on Date: October 23, 2015 (v1),Archive History for NCT02586805,ClinicalTrials.gov archive [online],2015年10月23日,URL,https://clinicaltrials.gov/ct2/history/NCT02533427
Annals of Allergy, Asthma & Immunology,2014年,Vol.113, No.4,p.460-466

Attorney, Agent or Firm:

Ryoichi Takaoka
Nao Oda
Akiyo Iwahori
Rena Miyoshi
Kamoto Takahashi

Previous Patent: Crane collision prevention device

Next Patent: Autonomous navigation with a spiking neuromorphic computer